BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
oleh: Margaux Poussard, Laure Philippe, Maxime Fredon, Elodie Bôle‐Richard, Sabeha Biichle, Florian Renosi, Sophie Perrin, Marie Kroemer, Samuel Limat, Francis Bonnefoy, Etienne Daguindau, Eric Deconinck, Bérengère Gruson, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, Fanny Angelot‐Delettre
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2021-02-01 |
Deskripsi
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these therapies, the influence of one on the other has to be explored. We set up a model to test the combination of polychemotherapy ‐ named methotrexate, idarubicine, dexamethasone, and L‐asparaginase (MIDA) ‐ and CD123 CAR‐T cell therapy. We showed that CD123 CAR‐T cells exert the same effect on BPDCN models alone, or after MIDA regimen. These data support a preclinical rationale to use immunotherapy after a treatment with polychemotherapy for BPDCN patients.